Gilbert & Cook’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Gilbert & Cook’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-3,243	Closed	-$259K	–	225
2022 Q2	$259K	Sell	3,243 -1,237	-28%	-$117K	0.05%	172
2022 Q1	$471K	Buy	4,480 +218	+5%	+$21.2K	0.08%	117
2021 Q4	$459K	Buy	4,262 +67	+2%	+$7.31K	0.07%	119
2021 Q3	$460K	Buy	4,195 +143	+4%	+$14.8K	0.08%	115
2021 Q2	$379K	Buy	4,052 +714	+21%	+$65.7K	0.07%	134
2021 Q1	$307K	Buy	+3,338	New	+$282K	0.06%	145
2020 Q4	–	Sell	-3,222	Closed	-$223K	–	195
2020 Q3	$223K	Buy	+3,222	New	+$222K	0.05%	138

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Gilbert & Cook's HZNP Position: Q3 2022 in Review

Gilbert & Cook sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q3 2022, closing a stake of 3,243 shares — an estimated $259K sold.

Gilbert & Cook first reported a position in HZNP in Q3 2020 and held it in 7 quarters. The position peaked at $471K in Q1 2022. 529 funds tracked by Wall St. Rank hold HZNP as of Q3 2022.

Gilbert & Cook reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q3 2022 after selling out during the quarter.
Gilbert & Cook sold 3,243 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2022, an estimated $259K.
Gilbert & Cook first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2020 and held it in 7 quarters.
Gilbert & Cook's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $471K in Q1 2022.
529 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2022.

Based on Gilbert & Cook's 13F filing for Q3 2022, filed 3 Nov 2022.